Vera Therapeutics reports wider Q2 net loss of $109.5 million as TRUTAKNA launches
Vera Therapeutics reported a second-quarter 2026 net loss of $109.5 million, or $1.52 per share, up from $76.5 million, or $1.20 per share, a year earlier. The company also said the FDA granted accelerated approval to TRUTAKNA for adults with primary IgA nephropathy at risk for disease progression, and that U.S. commercial launch is underway.
Key points
- Q2 2026 net loss was $109.5 million ($1.52 per share), versus $76.5 million ($1.20 per share) in Q2 2025.
- TRUTAKNA received FDA accelerated approval for adult primary IgAN patients at risk for disease progression.
- Cash, cash equivalents and marketable securities were $499.2 million at June 30, 2026, plus up to $425 million available under a debt facility, subject to conditions.
- Final ORIGIN 3 efficacy analysis is expected in Q3 2026, and the sBLA submission is expected in Q4 2026.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.